Dergiler / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 12

Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease

Sayfa
1025–1029
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It is also possible that this imbalance in thecoagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatorybowel disease (IBD).
📊
Temel Bulgular & Veri:The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13)in patients with IBD and to assess their possible role in the etiopathogenesis of the disease.Materials and Methods: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn’s disease) and 20 healthy controls were included in the present study.
💡
Sonuç & Katkı:It is also possible that this imbalance in thecoagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatorybowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13)in patients with IBD and to assess their possible role in the etiopathogenesis of the disease.Materials and Methods: Thirty-four patients with IBD (23 ulcerative colitis and 11 Crohn’s disease) and 20 healthy controls were included in the present study. TAFI, TFPI, and ADAMTS-13 concentrations were determined by enzyme-linked immunosorbent assay.Results: Mean TAFI, TFPI, and ADAMTS-13 concentrations in the patient group were 17.75 ng/ml, 72.10 ng/ml, and 14.90 U/l, respectively. In the control group, these values were 117.10 ng/ml, 300 ng/ml, and 191.55 U/l, respectively. TAFI, TFPI, and ADAMTS-13 values weresignificantly lower in the patient group than in the control group (all p<0.01).Conclusion: TAFI, TFPI, and ADAMTS-13 levels were significantly lower in the patient group. These findings indicate the presence of aclear, multifactorial imbalance in the coagulation–fibrinolytic system in the patient group. It is also possible that this imbalance in thecoagulation and fibrinolytic system may play a role in the still unclear etiopathogenesis of the disease.

🔖

Bu Makaleye Atıf Yap

YÜZBAŞIOĞLU, B., USTAOĞLU, M., YÜZBAŞIOĞLU, Ş., AKBULUT, U. E., ÖZDİL, K. (2019). Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 12, 1025–1029. https://ajindex.com/articles/408815

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Bernhard H, Deutschmann A, Leschnik B, et al. Thrombin generation in pediatric patients with Crohn’s disease. Inflamm Bowel Dis 2011
  2. [CrossRef] 2. Maher MM, Soloma SH. Assesment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saudi J Gastroenterol 2008
  3. [CrossRef] 3. Said Y, Hamzaoui L, El Jeri K, et al. Prevalence and risk factors of thromboembolic complications in inflammatory bowel disease. Tunis Med 2011
  4. Dogan Y, Soylu A, Eren GA, et al. Evaluation of QT and P wave dispersion and mean platelet volume among inflammatory bowel disease patients. Int J Med Sci 2011
  5. [CrossRef] 5. Hall CL, Zaman FS. A computational analysis of an in vitro vessel wall injury model. Ann Biomed Eng 2012
  6. [CrossRef] 6. Holroyd EW, White TA, Pan S, Simari RD. Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure. Front Biosci 2012
  7. [CrossRef] 7. Lippi G, Favaloro EJ. Coagulopathies and thrombosis: usual and unusual cuses and associations, part VI. Semin Thromb Hemost 2012
  8. [CrossRef] 8. Winckers K, Siegerink B, Duckers C, et al. Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost 2011
  9. [CrossRef] 9. Peraramelli S, Rosing J, Hackeng TM. TFPI-dependent activities of protein S. Thromb Res 2012: 129: 23-6. [CrossRef] 10. Reichman-Warmusz E, Kurek J, Gabriel A, et al. Tissue hemostasis and chronic inflammation in colon biopsies of patients with inflammatory bowel disease. Pathol Res Pract 2012
  10. [CrossRef] 11. Reijerkerk A, Voest EE, Gebbink MF. No grip, no growth: The conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 2000
  11. [CrossRef] 12. Colucci M, Semeraro N. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinoliysis and inflammation. Thromb Res 2012
  12. [CrossRef] 13. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007
  13. [CrossRef] 14. Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013
  14. [CrossRef] 15. Edwards NC, Hing ZA, Perry A, et al. Characterization of coding synonymous and non-synonymous vairants in A